+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers



The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers



European Journal of Clinical Pharmacology 69(4): 835-842



Sirolimus and tacrolimus are immunosuppressive compounds that have been used concomitantly in renal transplant patients. Both drugs are dosed orally and have common intestinal and hepatic metabolism and intestinal transport mechanisms. As such, there is a potential for pharmacokinetic drug interaction. A single-dose, open-label, four-period, four-treatment, randomized crossover study was conducted in 27 healthy fasting volunteers. Each subject received a 15-mg oral dose of sirolimus alone, a 10-mg oral dose of tacrolimus alone, sirolimus and tacrolimus administered simultaneously, and tacrolimus administered 4 h before sirolimus. Whole blood and plasma samples for sirolimus and tacrolimus testing were analyzed by liquid chromatography/tandem mass spectrometry. Pharmacokinetic parameters were assessed using noncompartmental methods and were compared using analysis of variance (ANOVA). The geometric mean ratio and 90 % confidence interval (CI) area under the concentration-time curve from time 0 to infinity (AUCinf) for sirolimus administered simultaneously with tacrolimus versus sirolimus alone were 97 and 89-106, respectively, and, when administered in a staggered approach versus sirolimus alone, 107 and 98-117, respectively. The geometric mean ratio (%) and 90 % CI AUCinf for tacrolimus administered simultaneously with sirolimus versus tacrolimus alone were 92 and 82-102, respectively, and, when administered in a staggered approach versus tacrolimus alone, 94 and 84-105, respectively. The results of this study demonstrate a lack of any clinically important drug interaction between sirolimus and tacrolimus in healthy subjects after single-dose administration. However, due to the complexity of anti-rejection immunosuppressive therapy dosing, we suggest that sirolimus and tacrolimus concentration monitoring be performed when changes in dosing are made for either drug regimen.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056335118

Download citation: RISBibTeXText

PMID: 23052408

DOI: 10.1007/s00228-012-1407-2


Related references

Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. Journal of Clinical Pharmacology 41(2): 217-223, 2001

Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. Pharmacology 99(1-2): 84-88, 2017

Pharmacokinetic interaction between single oral doses of ditiazem and sirolimus in healthy volunteers. Clinical Pharmacology & Therapeutics 69(1): 32-40, 2001

Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers. Clinical Drug Investigation 18(2): 141-150, 1999

A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 37, 2003

Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. International Journal of Clinical Pharmacology and Therapeutics 49(12): 756-764, 2011

Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 56(5): 1622-1630, 2012

Lack of pharmacokinetic interaction co-administered of sirolimus and tacrolimus. Clinical Pharmacology & Therapeutics 73(2): P43, 2003

Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. Pharmacology 98(3-4): 190-198, 2016

Assessment of the pharmacokinetic , pharmacodynamic interaction potential between posaconazole and glipizide in healthy volunteers. Clinical Pharmacology & Therapeutics 73(2): P45, 2003

Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 47(9): 564-569, 2009

Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. European Journal of Clinical Pharmacology 32(4): 389-393, 1987

Evaluation of the pharmacokinetic interaction between phenytoin and nelfinavir in healthy volunteers at steady state. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 14, 2000

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Clinical Drug Investigation 37(3): 303-309, 2017